Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Trial in progress: PROSERA, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension

Saturday, March 22, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The PROSERA trial is a Phase 3 study evaluating the efficacy and safety of seralutinib in adults suffering from pulmonary arterial hypertension (PAH). This study aims to provide crucial data that could support the therapeutic use of seralutinib in this patient population, addressing a significant medical need.
Price reaction · baseline $1.39 (2025-03-21 close) · hit after-hours · clean, no other GOSS news in the window
day 0 close
-7.9%
day 1
-7.9%
day 3 · peak
-16.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Phase 3 study indicates advanced research on seralutinib.
  • Focus on efficacy and safety in a critical patient population.
  • Potential to address unmet needs in pulmonary arterial hypertension.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Trial in progress: PROSERA, a phase 3 study of the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the PROSERA trial about?

The PROSERA trial is a Phase 3 study assessing the efficacy and safety of seralutinib in adults with pulmonary arterial hypertension.

What condition does seralutinib target?

Seralutinib is being studied for its effects on pulmonary arterial hypertension (PAH).

What phase is the PROSERA study in?

The PROSERA study is currently in Phase 3.

Who are the participants in the trial?

The trial involves adults diagnosed with pulmonary arterial hypertension.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension PROSERA clinical trial
Last updated: Mar 22, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →